Phase 1 Dose Escalation Trial of Ilorasertib, a Dual Aurora/VEGF Receptor Kinase Inhibitor, in Patients With Hematologic Malignancies

BACKGROUND: Ilorasertib (ABT-348) is a novel inhibitor of Aurora kinase, vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptors, and the Src families of tyrosine kinases. Ilorasertib alone or in combination with azacitidine demonstrated activity in preclinical models...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Invest New Drugs
Autores principales: Garcia-Manero, Guillermo, Tibes, Raoul, Kadia, Tapan, Kantarjian, Hagop, Arellano, Martha, Knight, Emily A., Xiong, Hao, Qin, Qin, Munasinghe, Wijith, Roberts-Rapp, Lisa, Ansell, Peter, Albert, Daniel H., Oliver, Brian, McKee, Mark D., Ricker, Justin L., Khoury, Hanna Jean
Formato: Artigo
Lenguaje:Inglês
Publicado: 2015
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5563391/
https://ncbi.nlm.nih.gov/pubmed/25933833
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-015-0242-6
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares